Wright Investors Service Inc. lowered its position in Shire PLC (NASDAQ:SHPG) by 31.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,007 shares of the biopharmaceutical company’s stock after selling 1,358 shares during the period. Wright Investors Service Inc.’s holdings in Shire PLC were worth $460,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hartford Financial Management Inc. increased its position in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of Shire PLC by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares in the last quarter. Pacer Advisors Inc. bought a new stake in shares of Shire PLC in the 2nd quarter valued at $171,000. Iberiabank Corp bought a new stake in shares of Shire PLC in the 2nd quarter valued at $203,000. Finally, Stephens Inc. AR increased its position in shares of Shire PLC by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares in the last quarter. Institutional investors and hedge funds own 19.27% of the company’s stock.
A number of research firms recently commented on SHPG. BidaskClub cut shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Barclays PLC cut shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Evercore ISI began coverage on shares of Shire PLC in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price objective for the company. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price objective on shares of Shire PLC and gave the company a “hold” rating in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $211.00.
COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Position Lowered by Wright Investors Service Inc.” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2017/11/02/shire-plc-shpg-position-lowered-by-wright-investors-service-inc.html.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same period last year, the firm posted $3.17 earnings per share. The company’s revenue for the quarter was up 7.1% on a year-over-year basis.
The business also recently declared a semiannual dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 8th were paid a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date of this dividend was Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 17.23%.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.